HA14-1

• Description :

  HA14-1 is a Bcl-2/Bcl-XL antagonist. HA14-1 binds the designated pocket on Bcl-2 with the IC50 of ≈9 μM in competing with the Bcl-2 binding of Flu-BakBH3, and inhibits its function.

• CAS Number :

  [65673-63-4]

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Bcl-2 Family

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/HA14-1.html

• Concentration :

  10mM

• Purity :

  98.0

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  CCOC(C1=C(N)OC2=CC=C(Br)C=C2[C@@]1([H])[C@H](C#N)C(OCC)=O)=O

• Molecular Formula :

  C17H17BrN2O5

• Molecular Weight :

  409.23

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Wang JL, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2000 Jun 20;97 (13) :7124-9.|[2]Kessel D, et al. Initiation of apoptosis and autophagy by the Bcl-2 antagonist HA14-1. Cancer Lett. 2007 May 8;249 (2) :294-9.|[3]Manero F, et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res. 2006 Mar 1;66 (5) :2757-64.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Bcl-2; Bcl-xL